Nemvaleukin alfa |
| カタログ番号GC72433 |
Nemvaleukin alfa (ALKS 4230) is a IL-2 fusion protein that selectively binds to intermediate-affinity IL-2R.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2315268-27-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Nemvaleukin alfa activates lymphocyte subsets from cynomolgus monkey and human samples, with EC50s of 0.45-2.2 nM[2].
Nemvaleukin alfa (0-100 nM, 30 min) induces the activation of intermediate-affinity IL-2R on human cells (HH cells)[3].
Nemvaleukin alfa (0-100 nM, 30 min) induces pSTAT5 in NK cells with an EC50 of 0.45 nM[3].
Nemvaleukin alfa (0.5 nM, 5 days) induces the activation of effector lymphocytes isolated from human peripheral blood[3].
Nemvaleukin alfa (6 mg/kg, s.c., every 4 days) inhibits SCLC tumor growth in mice[1].
References:
[1]. Pan Y, et al, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer. 2022 Sep;10(9):e004913.
[2]. Lopes JE, et al. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys. J Pharmacol Exp Ther. 2021 Nov;379(2):203-210.
[3]. Lopes JE, et al. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy. J Immunother Cancer. 2020 Apr;8(1):e000673.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *